Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 68Lung Neoplasms 18Neoplasms 7Neoplasm Metastasis 7Melanoma 5Carcinoma 5Mesothelioma, Malignant 4Colorectal Neoplasms 4Parkinson Disease 4, Autosomal Dominant Lewy Body 3Ovarian Neoplasms 3Carcinoma, Transitional Cell 3Squamous Cell Carcinoma of Head and Neck 2Pancreatic Neoplasms 2Non-Squamous Non-small Cell Lung Cancer 2Non-Small Cell Lung Cancer Metastatic 2Non Small Cell Lung Carcinoma NSCLC 2Mesothelioma 2Endometrial Neoplasms 2Brain Neoplasms 2Advanced Solid Tumors 2Uveal Melanoma 1Uterine Cervical Neoplasms 1Stomach Neoplasms 1Solitary Fibrous Tumor, Pleural 1Salivary Gland Neoplasms 1Resectable Stage IIA to IIIB Non-small Cell Lung Cancer 1Resectable Non-small Cell Lung Cancer 1Recurrent Metastatic Non-Squamous Non Small Cell Lung Cancer 1Rectal Neoplasms 1Primary Myelofibrosis 1

Interventions

pembrolizumab 1lenvatinib 1Pemetrexed 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Non-squamous Non-small-cell Lung Cancer × Pemetrexed × Clear all
NCT05258279 2024-08-28

Lenvatinib in Combination With Carboplatin Pemetrexed and Pembrolizumab for NSCLC With EGFR Mutations

Juntendo University

Phase 2 Active not recruiting
30 enrolled
Thoracic

Non-squamous Non-small-cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡